P2X Purinergic Receptor Neurons are neurons that express P2X receptors, a family of ATP-gated ion channels that play crucial roles in fast synaptic transmission, pain sensing, and neurodegenerative processes. These receptor neurons are widely distributed throughout the central and peripheral nervous systems and represent important therapeutic targets for neurological disorders[1].
P2X receptors are cationic channels activated by extracellular adenosine triphosphate (ATP). Seven subtypes (P2X1-P2X7) have been identified, each with distinct pharmacological properties and anatomical distributions. P2X receptors mediate rapid responses to synaptic ATP release, making them critical for neural communication.
| Receptor | Distribution | Function | Therapeutic Target |
|---|---|---|---|
| P2X1 | DRG, smooth muscle | Urinary bladder | Yes |
| P2X2 | CNS, autonomic | Synaptic transmission | Potential |
| P2X3 | DRG,nociceptors | Pain signaling | Yes |
| P2X4 | CNS, microglia | Astrocyte signaling | Potential |
| P2X5 | Spinal cord | Motor function | No |
| P2X6 | CNS | Modulatory | No |
| P2X7 | Immune cells, glia | Inflammatory | Yes |
P2X receptors are ATP-gated ion channels that permit Na+ and Ca2+ influx upon activation. The signaling cascade involves[2]:
P2X receptor overactivation contributes to excitotoxic cell death[3]:
P2X7 receptor expression is elevated in ALS:
P2X receptors are critical for nociception, particularly P2X3 and P2X2/3[4].
| Target | Drug | Status | Indication |
|---|---|---|---|
| P2X3 | gefaprixant | Phase 3 | Chronic cough |
| P2X3 | Blu-4702 | Phase 2 | Overactive bladder |
| P2X7 | CE-224545 | Discontinued | RA |
P2X receptors are validated drug targets:
P2X receptors play complex roles in PD pathogenesis[5]:
Dopaminergic Neuron Vulnerability
Neuroinflammation
Therapeutic Potential
In AD, P2X receptors contribute to pathology[6]:
| Mechanism | P2X Involved | Effect |
|---|---|---|
| Amyloid-β interaction | P2X4, P2X7 | Enhanced toxicity |
| Calcium dysregulation | All subtypes | Synaptic failure |
| Neuroinflammation | P2X7 | Microglial activation |
| Memory impairment | P2X2, P2X4 | Cognitive deficits |
Amyloid-beta Interaction
Therapeutic Targeting
Biomarker Potential
P2X receptors are involved in ALS:
Motor Neuron Degeneration
Microglial Contributions
Therapeutic Approaches
In demyelinating diseases:
Oligodendrocyte Vulnerability
Therapeutic Potential
P2X receptors are emerging targets in psychiatry[7]:
| Finding | Mechanism | Treatment |
|---|---|---|
| Elevated P2X7 | Inflammation | P2X7 antagonists |
| Reduced P2X2 | Synaptic dysfunction | P2X2 agonists |
| Altered P2X4 | Microglial activation | P2X4 modulators |
Monoamine Interaction
Inflammatory Link
Clinical Trials
P2X receptors in anxiety:
Findings in schizophrenia[8]:
P2X receptors in seizure disorders[9]:
Seizure Initiation
ictal Spread
Therapeutic Targeting
In prolonged seizures:
P2X3 and P2X2/3 are primary pain receptors[10]:
| Receptor | Location | Function |
|---|---|---|
| P2X3 | DRG, nociceptors | Acute pain |
| P2X2/3 | DRG, interneurons | Chronic pain |
| P2X4 | Dorsal horn | Neuropathic pain |
| P2X7 | Immune cells | Inflammatory pain |
P2X4 underlies neuropathic pain[11]:
Microglial P2X4 Activation
Pain Transmission
Therapeutic Approaches
P2X7 in inflammatory pain:
| Drug | Target | Phase | Indication |
|---|---|---|---|
| Gefaprixant | P2X3 | Phase 3 | Chronic cough |
| Blu-4702 | P2X3 | Phase 2 | OAB |
| CE-224545 | P2X7 | Discontinued | RA |
| JNJ-54179060 | P2X7 | Phase 2 | Depression |
| JNJ-42253452 | P2X3 | Phase 1 | Pain |
| Challenge | Approach |
|---|---|
| CNS penetration | Lipophilicity |
| Selectivity | Structure-based design |
| Chronic dosing | Slow-release formulations |
| Side effects | Tissue-selective targeting |
Subtype-Selective Drugs
Combination Therapies
| Model | Application | Advantages |
|---|---|---|
| Xenopus oocytes | Electrophysiology | Fast screening |
| HEK293 cells | Pharmacology | Easy transfection |
| Primary neurons | CNS studies | Physiological |
| DRG cultures | Pain research | Relevant |
| Marker | Sample | Disease Relevance |
|---|---|---|
| P2X7 | CSF | Neuroinflammation |
| P2X4 | Blood | Pain |
| ATP release | Microdialysis | Activity |
| Agonist | Selectivity | Use |
|---|---|---|
| α,β-MeATP | P2X1, P2X3 | Research |
| BzATP | P2X7 | Research |
| ATP | Pan-P2X | Physiological |
| Antagonist | Selectivity | IC50 |
|---|---|---|
| TNP-ATP | P2X1-3 | 10 nM |
| A-438079 | P2X7 | 10 nM |
| suramin | Pan-P2X | 1 μM |
| BBG | P2X7 | 100 nM |
Key structural features for antagonism:
| Biomarker | Selection Criteria |
|---|---|
| P2X7 expression | Elevated in disease |
| Pain threshold | P2X3 involvement |
| Inflammation | P2X7 activation |
| Co-medications | Interaction |
|---|---|
| Opioids | Additive analgesia |
| NSAIDs | Anti-inflammatory |
| Gabapentinoids | Synergistic |
Purinergic signalling. Experimental Neurology. 2008. ↩︎
P2 receptor signaling in neurodegeneration. Trends in Pharmacological Sciences. 2005. ↩︎
Purinergic signaling in brain disease. Nature Reviews Neuroscience. 2009. ↩︎
P2X receptors as pain targets. Pharmacology & Therapeutics. 2018. ↩︎
Purinergic signaling in Parkinson's. Progress in Neurobiology. 2012. ↩︎
P2X receptors in Alzheimer's. Aging Cell. 2013. ↩︎
ATP-gated ion channels in depression. Molecular Psychiatry. 2019. ↩︎
P2X7 in psychiatric disorders. Neuropsychopharmacology. 2019. ↩︎
P2X in epilepsy. Epilepsia. 2014. ↩︎
P2X3 antagonists for chronic pain. European Journal of Pharmacology. 2018. ↩︎
P2X4 receptors in neuropathic pain. Pain. 2014. ↩︎